United Therapeutics Launches Major Accelerated Share Repurchase Program

Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potentialUnited Therapeutics ( (UTHR) ) just unveiled an announcement. United Therapeutics’ board on March 8, 2026 authorized a new stock repurchase program of up to $2 billion through March 9, 2027, signaling confidence in the company’s growth prospects and cash-flow trajectory. Management framed the move as a response to what it sees as a disconnect between the firm’s fundamentals and its market valuation, positioning the buyback as a value-enhancing capital allocation decision for shareholders. On March 9, 2026, the company executed two accelerated share repurchase agreements with Citibank totaling $1.5 billion, split evenly between an uncollared and a collared structure, with initial share deliveries due around March 11, 2026 and final settlement tied to volume-weighted average prices later in 2026. The remaining $500 million authorization can be deployed at the company’s discretion over the next year, giving United Therapeutics flexibility to continue shrinking its float and potentially boosting earnings per share while maintaining what it describes as a robust balance sheet. The most recent analyst rating on (UTHR) stock is a Buy with a $705.00 price target. To see the full list of analyst forecasts on United Therapeutics stock, see the UTHR Stock Forecast page. Spark’s Take on UTHR Stock According to Spark, TipRanks’ AI Analyst, UTHR is a Outperform. The score is driven primarily by outstanding financial strength (high profitability, rising earnings, and debt eliminated) and supportive technicals (price above key moving averages with healthy momentum). Earnings-call commentary adds upside potential via reiterated growth outlook and multiple near-term pipeline catalysts, tempered by competitive dynamics, sales variability, and binary readout/approval risk; valuation appears reasonable but not notably cheap. To see Spark’s full report on UTHR stock, click here. More about United Therapeutics United Therapeutics Corporation is a public benefit biotechnology company focused on transforming the treatment of rare diseases, notably pulmonary arterial hypertension, and pioneering technologies to expand the supply of transplantable organs. Founded by CEO Martine Rothblatt, the company emphasizes rapid translation of scientific advances into therapies and manufactured organs, while balancing patient care, long-term shareholder value and sustainable business practices. Average Trading Volume: 406,914 Technical Sentiment Signal: Buy Current Market Cap: $20.96B For a thorough assessment of UTHR stock, go to TipRanks’ Stock Analysis page.